101 related articles for article (PubMed ID: 19610324)
1. Comment on "An experimental palladium-103 seed (OptiSeedexp in a biocompatible polymer without a gold marker: characterization of dosimetric parameters including the interseed effect" [Med. Phys. 35, 5841-5850 (2008)].
Pignol JP; Keller BM
Med Phys; 2009 Jun; 36(6):2343; author reply 2344. PubMed ID: 19610324
[No Abstract] [Full Text] [Related]
2. An experimental palladium-103 seed (OptiSeedexp) in a biocompatible polymer without a gold marker: characterization of dosimetric parameters including the interseed effect.
Abboud F; Scalliet P; Vynckier S
Med Phys; 2008 Dec; 35(12):5841-50. PubMed ID: 19175140
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric study of a new polymer encapsulated palladium-103 seed.
Bernard S; Vynckier S
Phys Med Biol; 2005 Apr; 50(7):1493-504. PubMed ID: 15798339
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo and experimental characterization of the first AMIRS 103Pd brachytherapy source.
Raisali G; Ghonchehnazi MG; Shokrani P; Sadeghi M
Appl Radiat Isot; 2008 Dec; 66(12):1856-60. PubMed ID: 18657981
[TBL] [Abstract][Full Text] [Related]
5. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
Thomson RM; Rogers DW
Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
7. Monte Carlo-aided dosimetry of the theragenics TheraSeed model 200 103Pd interstitial brachytherapy seed.
Monroe JI; Williamson JF
Med Phys; 2002 Apr; 29(4):609-21. PubMed ID: 11991133
[TBL] [Abstract][Full Text] [Related]
8. Comment on "Update of AAPM Task Group no. 43 report: A revised AAPM protocol for brachytherapy dose calculations" [Med. Phys. 31, 633-674 (2004)].
Meigooni AS; Rachabatthula V; Awan SB; Koona RA
Med Phys; 2005 Jun; 32(6):1820-1; author reply 1822-4. PubMed ID: 16013739
[No Abstract] [Full Text] [Related]
9. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
Lesperance M; Martinov M; Thomson RM
Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
[TBL] [Abstract][Full Text] [Related]
10. Consequences of dose heterogeneity on the biological efficiency of ¹⁰³Pd permanent breast seed implants.
Afsharpour H; Reniers B; Landry G; Pignol JP; Keller BM; Verhaegen F; Beaulieu L
Phys Med Biol; 2012 Feb; 57(3):809-23. PubMed ID: 22252246
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant.
Furstoss C; Reniers B; Bertrand MJ; Poon E; Carrier JF; Keller BM; Pignol JP; Beaulieu L; Verhaegen F
Med Phys; 2009 May; 36(5):1848-58. PubMed ID: 19544804
[TBL] [Abstract][Full Text] [Related]
12. Response to "Comment on 'AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137'" [Med. Phys. 36, 5310-5322 (2009)].
Nath R; Bice WS; Butler WM; Chen Z; Meigooni AS; Narayana V; Rivard MJ; Yu Y
Med Phys; 2010 Apr; 37(4):1933. PubMed ID: 20443515
[No Abstract] [Full Text] [Related]
13. Monte Carlo and experimental dosimetry of an 1251 brachytherapy seed.
Dolan J; Lia Z; Williamson JF
Med Phys; 2006 Dec; 33(12):4675-84. PubMed ID: 17278820
[TBL] [Abstract][Full Text] [Related]
14. Experimental and theoretical dosimetry of a new polymer encapsulated iodine-125 source--SmartSeed: dosimetric impact of fluorescence x rays.
Abboud F; Hollows M; Scalliet P; Vynckier S
Med Phys; 2010 May; 37(5):2054-62. PubMed ID: 20527538
[TBL] [Abstract][Full Text] [Related]
15. Polymer gel dosimetry for the TG-43 dosimetric characterization of a new 125I interstitial brachytherapy seed.
Papagiannis P; Pantelis E; Georgiou E; Karaiskos P; Angelopoulos A; Sakelliou L; Stiliaris S; Baltas D; Seimenis I
Phys Med Biol; 2006 Apr; 51(8):2101-11. PubMed ID: 16585848
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric parameters of the new design (103)Pd brachytherapy source based on Monte Carlo study.
Saidi P; Sadeghi M; Shirazi A; Tenreiro C
Phys Med; 2012 Jan; 28(1):13-8. PubMed ID: 21251862
[TBL] [Abstract][Full Text] [Related]
17. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
Thomson RM; Taylor RE; Rogers DW
Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric characterization of model Cs-1 Rev2 cesium-131 brachytherapy source in water phantoms and human tissues with MCNP5 Monte Carlo simulation.
Wang J; Zhang H
Med Phys; 2008 Apr; 35(4):1571-9. PubMed ID: 18491551
[TBL] [Abstract][Full Text] [Related]
19. A modern Monte Carlo investigation of the TG-43 dosimetry parameters for an 125I seed already having AAPM consensus data.
Aryal P; Molloy JA; Rivard MJ
Med Phys; 2014 Feb; 41(2):021702. PubMed ID: 24506593
[TBL] [Abstract][Full Text] [Related]
20. Monte Carlo calculation of dosimetry parameters for the IR08-103Pd brachytherapy source.
Saidi P; Sadeghi M; Shirazi A; Tenreiro C
Med Phys; 2010 Jun; 37(6):2509-15. PubMed ID: 20632562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
